Amplyx Pharmaceuticals names new COO and SVP, clinical development
9 June 2020 -

Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company, has named Chris LeMasters as its new chief operating officer and Carlos Sattler MD as its new senior vice president, clinical development, it was reported on Monday.

LeMasters is to lead operations and corporate development, and direct the company's finance and administrative functions. He has also served as chief business officer of Mirati Therapeutics.

Dr Sattler has served in various leadership roles at companies including Halozyme, Sandoz, and Merck. In the new role, Sattler will head the clinical development program for the company's novel, first-in-class antifungal drug candidate, fosmanogepix.